AGM Statement

Alliance Pharma PLC

25 May 2023

 

For immediate release

25 May 2023

ALLIANCE PHARMA

("Alliance", "Company" or the "Group")

AGM statement

Alliance Pharma plc (AIM: APH), the international consumer healthcare company, will hold its Annual General Meeting ("AGM") at 09:00am this morning. At the meeting, the Group's Chair, David Cook, will make the following statement:

"Sales for the first four months of the year are ahead of the equivalent period in 2022.

"In-market demand for Kelo-Cote™ in China has continued the recovery we referenced in our preliminary results announcement in March and is building in-line with our expectations.

"Whilst the business is on track to meet the Board's full year expectations for revenue and adjusted EBITDA, adverse currency movements, particularly the recent strengthening of UK sterling against the US dollar, and the rising interest rate environment, mean that full year adjusted profit before tax is expected to be marginally below current expectations.

"Further detail will be provided in the interim trading update scheduled for 18 July 2023."

For further information:

Alliance Pharma plc	+ 44 (0)1249 466966
Cora McCallum, Head of Investor Relations & Corporate Communications	+ 44 (0)1249 705168
[e-mail]
Buchanan	+ 44 (0)20 7466 5000
Mark Court / Hannah Ratcliff
[e-mail]
Numis Securities Limited (Nominated Adviser and Joint Broker)	+ 44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith / Sher Shah
Investec Bank plc (Joint Broker)	+ 44 (0)20 7597 5970
Patrick Robb

About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

 

END